# Retatrutide clinical trials: design, status and registry dates

> Compare retatrutide trial identifiers, phases, masking, comparators and registry dates, with abbreviated assessment windows and verification limits.

- URL: https://aloraresearch.com/research/notes/retatrutide-clinical-trials
- Published: 2026-10-15
- Last reviewed: 2026-10-15
- ALORA Research editorial team

## The short answer

Retatrutide clinical trials include NCT04881760, a registered phase 2 study with COMPLETED status; TRIUMPH-1, a registered phase 3 study with COMPLETED status; and TRANSCEND-T2D-2, a registered phase 3 study with ACTIVE_NOT_RECRUITING status and a semaglutide comparator. These are transcribed registry fields, not live verification; the tracker compares administrative and design fields, not primary endpoint measurements.

## Key facts

- **Registry research names:** Retatrutide; LY3437943  [1]
- **Registered phase 2 example:** NCT04881760: COMPLETED  [2]
- **Registered phase 3 comparator:** NCT06260722: semaglutide  [3]
- **Record update example:** TRIUMPH-Outcomes: 2026-10-08  [4]
- **Separate registry category:** EXPANDED_ACCESS; AVAILABLE  [5]

## Retatrutide clinical trials: what is registered?

Registry records identify Retatrutide as LY3437943 and include interventional studies plus a separately classified expanded-access record. [1, 5]

An interventional study assigns a research intervention to study participants. A registry identifier identifies the study, rather than a publication or a catalog material. Read the table by identifier: program names are useful labels, but they do not replace the individual record.

Coverage is limited to the identifiers below. The comparison transcribes recorded fields; it does not certify an exhaustive registry search or live verification. This tracker is limited to administrative and design fields, with abbreviated assessment windows; it does not compare primary endpoint measurements. Complete endpoint wording, subsets and measurement-specific reference points remain in each cited registry entry.

For compound-level context, see the [Retatrutide catalog record](https://aloraresearch.com/products/retatrutide) and the [receptor and structure overview](https://aloraresearch.com/research/notes/what-is-retatrutide).

## Which studies are registered, and how do their fields compare?

The registered studies distinguish phase, allocation, masking, comparator and administrative status as separate fields. [1, 2, 3]

Allocation describes assignment to study groups; randomized assignment uses chance. Masking means concealing assignment information from specified study roles. An active comparator is another compound used for comparison. The table retains the masking codes DOUBLE, SINGLE and NONE without inferring the roles involved.

A primary endpoint is a prespecified main measurement. Primary completion concerns the final collection of primary-endpoint data; study completion concerns the final collection of all scheduled study data.

Assessment windows below are abbreviated, not statements of total study duration or a comparison of what each study measures. “Not separately listed” does not mean that a study lacks comparisons; it avoids assigning a comparator role that is not explicit in the summarized fields. “Not reported” marks an unfilled field in this comparison. Retrieval timestamp: unverified for every entry.

| Study / sponsor class | Phase | Allocation | Masking | Comparator | Status | Assessment window | Primary completion | Last update posted |
|---|---|---|---|---|---|---|---|---|
| NCT03841630 / INDUSTRY | 1 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Approximately Day 43 | Date: 2019-07-25 | Posted: 2019-08-06 [6] |
| NCT04143802 / INDUSTRY | 1 | RANDOMIZED | DOUBLE | Dulaglutide; placebo | COMPLETED | Baseline through Day 106 | Date: 2020-12-28 | Posted: 2021-01-20 [7] |
| NCT04823208 / INDUSTRY | 1 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline through Day 106 | Date: 2022-06-23 | Posted: 2022-08-22 [8] |
| NCT05445232 / INDUSTRY | 1 | NON_RANDOMIZED | NONE | Not separately listed | COMPLETED | Up to 24 hours; 96 hours; 48 hours | Date: 2023-02-24 | Posted: 2023-04-18 [9] |
| NCT05548231 / INDUSTRY | 1 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline through Week 20 | Date: 2023-07-27 | Posted: 2023-08-14 [10] |
| NCT05611957 / INDUSTRY | 1 | NON_RANDOMIZED | NONE | Not separately listed | COMPLETED | Up to 31 days | Date: 2023-09-05 | Posted: 2023-10-02 [11] |
| NCT05916560 / INDUSTRY | 1 | NON_RANDOMIZED | NONE | Not separately listed | COMPLETED | Up to 30 days | Date: 2025-03-02 | Posted: 2025-04-18 [12] |
| NCT05959096 / INDUSTRY | 1 | RANDOMIZED | NONE | Not separately listed | COMPLETED | Up to 43 days | Date: 2024-07-25 | Posted: 2024-10-01 [13] |
| NCT06003465 / INDUSTRY | 1 | RANDOMIZED | NONE | Test / reference | COMPLETED | Up to 43 days | Date: 2024-02-08 | Posted: 2024-03-29 [14] |
| NCT06039826 / INDUSTRY | 1 | NON_RANDOMIZED | NONE | Not separately listed | COMPLETED | Up to 144 days | Date: 2024-07-11 | Posted: 2024-07-26 [15] |
| NCT06808802 / INDUSTRY | 1 | NA | NONE | Not separately listed | COMPLETED | Day 1 to Day 3; Day 9 to Day 11 | Date: 2025-04-15 | Posted: 2025-06-05 [16] |
| NCT06982846 / INDUSTRY | 1 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Within 60 minutes | Date: 2026-05-04 | Posted: 2026-06-18 [17] |
| NCT04867785 / INDUSTRY | 2 | RANDOMIZED | DOUBLE | Dulaglutide; placebo | COMPLETED | Baseline, 24 Weeks | Date: 2022-07-08 | Posted: 2023-07-03 [18] |
| NCT04881760 / INDUSTRY | 2 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline, Week 24 | Date: 2022-05-16 | Posted: 2023-09-13 [2] |
| NCT05936151 / INDUSTRY | 2 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline, Week 24 | Date: 2025-10-01 | Posted: 2025-11-25 [19] |
| NCT07467447 / INDUSTRY | 2 | RANDOMIZED | SINGLE | Placebo | RECRUITING | 24 weeks | Date: 2027-03-14 | Posted: 2026-03-12 [20] |
| NCT05882045 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline, Week 80 | Date: 2026-04-16 | Posted: 2026-07-30 [21] |
| NCT05929066 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline, Week 80; Week 104 | Date: 2026-04-06 | Posted: 2026-08-21 [1] |
| NCT05929079 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline, Week 80 | Date: 2026-06-16 | Posted: 2026-07-30 [22] |
| NCT05931367 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline, Week 68 | Date: 2025-11-14 | Posted: 2026-01-21 [23] |
| NCT06260722 / INDUSTRY | 3 | RANDOMIZED | NONE | Semaglutide | ACTIVE_NOT_RECRUITING | Baseline, Week 80 | Date: 2026-08-27 | Posted: 2026-09-28 [3] |
| NCT06297603 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | ACTIVE_NOT_RECRUITING | Baseline, Week 52 | Date: 2026-10 | Posted: 2026-07-20 [24] |
| NCT06354660 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | COMPLETED | Baseline, Week 40 | Date: 2026-01-22 | Posted: 2026-03-05 [25] |
| NCT06383390 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | ACTIVE_NOT_RECRUITING | Approximate 248 Weeks | Date: 2029-02 | Posted: 2026-10-08 [4] |
| NCT06662383 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Tirzepatide | ACTIVE_NOT_RECRUITING | Baseline, Week 80 | Date: 2026-11 | Posted: 2026-07-20 [26] |
| NCT06859268 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | ACTIVE_NOT_RECRUITING | Week 0, Week 116 | Date: 2028-04 | Posted: 2026-03-03 [27] |
| NCT07035093 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | ACTIVE_NOT_RECRUITING | Baseline, up to 72 weeks | Date: 2027-09 | Posted: 2026-09-25 [28] |
| NCT07232719 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Placebo | ACTIVE_NOT_RECRUITING | Baseline, Week 56 | Date: 2027-07 | Posted: 2026-04-17 [29] |
| NCT07357415 / INDUSTRY | 3 | RANDOMIZED | DOUBLE | Not separately listed | ACTIVE_NOT_RECRUITING | Baseline, Week 104 | Date: 2028-10 | Posted: 2026-06-09 [30] |
| NCT07629401 / INDUSTRY | Not reported | Not reported | Not reported | Not reported | AVAILABLE | Not reported | Not reported | Posted: 2026-08-06 [5] |

The expanded-access row is retained for classification, not presented as an interventional phase study. [5]

## How do TRIUMPH and TRANSCEND-T2D designs differ?

The published TRIUMPH design describes double-blind, placebo-controlled phase 3 studies, whereas TRANSCEND-T2D registry records also include an open-label semaglutide comparison. [31, 3]

Open-label means that study assignment is not masked. The human TRIUMPH design report describes a basket design, with related study questions nested within overarching studies. [31]

Registered TRANSCEND-T2D-1 lists randomized allocation, DOUBLE masking and placebo comparison. [25] Registered TRANSCEND-T2D-2 lists randomized allocation, NONE masking and semaglutide comparison, while registered TRANSCEND-T2D-3 lists randomized allocation, DOUBLE masking and placebo comparison. [3, 24]

The separate registered phase 3 study NCT06662383 lists tirzepatide as its comparator and DOUBLE masking. [26] For compound-level distinctions, see [Retatrutide vs tirzepatide: receptors and comparison limits](https://aloraresearch.com/research/notes/retatrutide-vs-tirzepatide). Keep those distinctions separate from what a particular comparative study was designed to measure.

## What do status labels and completion dates mean?

Registry status is an administrative label, not a reported study result.

The following Spanish glosses explain the labels without replacing the original registry wording:

- **COMPLETED — completado:** study activities have concluded.
- **ACTIVE_NOT_RECRUITING — activo, sin reclutamiento:** the study remains active but is not recruiting.
- **RECRUITING — en reclutamiento:** the study is seeking participants.
- **AVAILABLE — disponible:** the label attached to the expanded-access record here, rather than a phase designation. [5]

Registered study NCT06260722 lists primary completion as 2026-08-27 but retains ACTIVE_NOT_RECRUITING in its 2026-09-28 update. [3] This example should be read as separate recorded fields, not as a reason to replace the status with an inferred label.

Actual-versus-estimated date qualifiers remain unverified in this comparison. Separate study-completion dates are not reproduced. Month-only dates remain month-only; they should not be interpreted as a particular day.

## What has changed since the previous registry update?

A last-update-posted date alone does not establish which status, design or endpoint fields changed.

The registered TRIUMPH-Outcomes record shows 2026-10-08 as its last-update-posted date, while registered study NCT07035093 shows 2026-09-25. [4, 28] Read these as record timestamps, not as a verified change log.

**Change-log status:** baseline field transcription only; no archived prior-version comparison is asserted.

For reproducible coverage, the refresh specification is to search ClinicalTrials.gov using both `retatrutide` and `LY3437943`, retain records explicitly identifying either research name, and deduplicate by study identifier. Interventional entries and expanded-access entries remain separately classified. These are inclusion rules, not a claim that a complete live search was executed.

A verifiable refresh would preserve the search terms, retrieval timestamp, record version and previous field values. A change entry would identify the affected study and distinguish a changed status from an amended design or endpoint. Until that comparison exists, “changed” should remain unverified rather than inferred from a publication date.

## How do trial records relate to catalog documentation?

Registry identity fields do not establish equivalence between catalog material and material described in a registered study. [1, 2]

A study identifier identifies a research study; a lot identifier identifies a particular material batch. A certificate of analysis is a document reporting analytical test results for an identified sample or lot.

For lot-specific documentation, consult the [Certificate of Analysis library](https://aloraresearch.com/research#coa). Keep the documentation questions separate: the registry is the reference for the study fields compared above, while lot documentation is the reference for the identified material. A shared compound name should not be read as a documented connection between them.

## What the research establishes

- Registered phase 2 studies include randomized, double-masked placebo-controlled designs, with dulaglutide also listed as a comparator in NCT04867785.  [2, 18]
- Registered phase 3 studies include semaglutide and tirzepatide comparisons with different masking fields.  [3, 26]
- The registered TRIUMPH-Outcomes study lists ACTIVE_NOT_RECRUITING status and a last-update-posted date of 2026-10-08.  [4]
- NCT07629401 is classified as EXPANDED_ACCESS and carries the status AVAILABLE.  [5]

## What it does not establish

- Exhaustive registry coverage and independently verified retrieval timestamps are not established by the individual study records.  [1, 2, 3, 4, 5]
- The listed primary-completion dates do not establish their actual-versus-estimated classification in this comparison.  [1, 3, 4]
- A last-update-posted date does not establish which status, design or endpoint fields changed from an earlier version.  [3, 4, 28]
- Registry identity fields do not establish equivalence between research catalog material and material described in a registered study.  [1, 2]

## Evidence at a glance

| Study | Year | Model | What was reported | Source |
| --- | --- | --- | --- | --- |
| NCT04881760 | 2021 | Trial registry | This registered phase 2 study lists randomized allocation, DOUBLE masking, a placebo comparator and COMPLETED status.  [2] | [2] |
| TRIUMPH-1 | 2023 | Trial registry | This registered phase 3 study lists randomized allocation, DOUBLE masking, a placebo comparator and primary assessment windows at Week 80 and Week 104.  [1] | [1] |
| TRANSCEND-T2D-2 | 2024 | Trial registry | This registered phase 3 study lists randomized allocation, NONE masking, a semaglutide comparator and ACTIVE_NOT_RECRUITING status.  [3] | [3] |
| NCT06662383 | 2024 | Trial registry | This registered phase 3 study lists randomized allocation, DOUBLE masking, a tirzepatide comparator and ACTIVE_NOT_RECRUITING status.  [26] | [26] |
| NCT07467447 | 2026 | Trial registry | This registered phase 2 study lists randomized allocation, SINGLE masking, a placebo comparator, INDUSTRY sponsor class and RECRUITING status.  [20] | [20] |
| Giblin et al. | 2026 | Human study | The human TRIUMPH design report describes phase 3 randomized, double-blind, placebo-controlled studies and a basket design with nested study questions.  [31] | [31] |

## Frequently asked questions

### Which retatrutide clinical trials are phase 2?

Registered phase 2 entries include NCT04881760, NCT04867785, NCT05936151 and NCT07467447.  [2, 18, 19, 20] NCT07467447 lists SINGLE masking and RECRUITING status, while the other named records list DOUBLE masking and COMPLETED status.  [2, 18, 19, 20]

### Which retatrutide phase 3 studies use an active comparator?

Registered phase 3 study NCT06260722 lists semaglutide, while NCT06662383 lists tirzepatide as the comparator.  [3, 26] Their masking fields differ: NCT06260722 lists NONE, whereas NCT06662383 lists DOUBLE.  [3, 26]

### Where are retatrutide registered primary endpoints listed?

The interventional registry records contain primary-outcome fields with assessment time frames.  [1, 2, 3] For example, registered study NCT05929066 includes primary assessment windows at Week 80 and Week 104.  [1] The table lists abbreviated assessment windows, not endpoint measurements; consult each cited record for complete endpoint wording, subsets and measurement-specific reference points.

### Is primary completion the same as study completion?

Primary completion concerns the final collection of primary-endpoint data; study completion concerns the final collection of all scheduled study data. Registered study NCT06260722 lists primary completion as 2026-08-27 while retaining ACTIVE_NOT_RECRUITING status in its 2026-09-28 update.  [3] A primary-completion date should therefore not replace the recorded status.

### What changed in the retatrutide registry since the previous update?

The registered TRIUMPH-Outcomes record lists 2026-10-08 as its last-update-posted date.  [4] That timestamp alone does not identify which fields changed. No comparison with an archived earlier record version is asserted here.

## References

1. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT05929066
2. A Study of LY3437943 in Participants Who Have Obesity or Are Overweight *ClinicalTrials.gov*. 2021. https://clinicaltrials.gov/study/NCT04881760
3. Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) *ClinicalTrials.gov*. 2024. https://clinicaltrials.gov/study/NCT06260722
4. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) *ClinicalTrials.gov*. 2024. https://clinicaltrials.gov/study/NCT06383390
5. Pre-approval Expanded Access of Retatrutide (LY3437943) *ClinicalTrials.gov*. 2026. https://clinicaltrials.gov/study/NCT07629401
6. A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants *ClinicalTrials.gov*. 2019. https://clinicaltrials.gov/study/NCT03841630
7. A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM) *ClinicalTrials.gov*. 2019. https://clinicaltrials.gov/study/NCT04143802
8. A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM) *ClinicalTrials.gov*. 2021. https://clinicaltrials.gov/study/NCT04823208
9. A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants *ClinicalTrials.gov*. 2022. https://clinicaltrials.gov/study/NCT05445232
10. A Study of LY3437943 in Chinese Participants With Obesity Or Overweight *ClinicalTrials.gov*. 2022. https://clinicaltrials.gov/study/NCT05548231
11. A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function *ClinicalTrials.gov*. 2022. https://clinicaltrials.gov/study/NCT05611957
12. A Study of LY3437943 in Participants With Impaired and Normal Liver Function *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT05916560
13. A Study of LY3437943 in Healthy Participants With a High Body Mass Index *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT05959096
14. A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT06003465
15. A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT06039826
16. To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants *ClinicalTrials.gov*. 2025. https://clinicaltrials.gov/study/NCT06808802
17. A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia *ClinicalTrials.gov*. 2025. https://clinicaltrials.gov/study/NCT06982846
18. A Study of LY3437943 in Participants With Type 2 Diabetes *ClinicalTrials.gov*. 2021. https://clinicaltrials.gov/study/NCT04867785
19. A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT05936151
20. Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight *ClinicalTrials.gov*. 2026. https://clinicaltrials.gov/study/NCT07467447
21. A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT05882045
22. A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT05929079
23. A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee *ClinicalTrials.gov*. 2023. https://clinicaltrials.gov/study/NCT05931367
24. Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) *ClinicalTrials.gov*. 2024. https://clinicaltrials.gov/study/NCT06297603
25. Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) *ClinicalTrials.gov*. 2024. https://clinicaltrials.gov/study/NCT06354660
26. A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity *ClinicalTrials.gov*. 2024. https://clinicaltrials.gov/study/NCT06662383
27. A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity *ClinicalTrials.gov*. 2025. https://clinicaltrials.gov/study/NCT06859268
28. A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain *ClinicalTrials.gov*. 2025. https://clinicaltrials.gov/study/NCT07035093
29. A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight *ClinicalTrials.gov*. 2025. https://clinicaltrials.gov/study/NCT07232719
30. A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight *ClinicalTrials.gov*. 2026. https://clinicaltrials.gov/study/NCT07357415
31. Giblin K, Kaplan LM, Somers VK, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials *Diabetes, obesity & metabolism*. 2026. https://pubmed.ncbi.nlm.nih.gov/41090431/

---

Research Notes summarize published scientific literature for laboratory research reference. They are not guidance on human or veterinary use, describe findings in the models studied only, and have not been evaluated by the FDA.